OK-102 (stearoyl-oligopeptide)
Sequence: CHHRRRRHHC
nkRNA1 (long ssRNA that self-anneals)
| Experiment Id | EXP001995 |
|---|---|
| Paper | Functional peptide nanocarriers for delivery of novel anti-RelA RNA interference agents as a topical |
| Peptide | OK-102 (stearoyl-oligopeptide) |
| Delivery Success Class | yes |
| In Vivo Flag | yes |
| Uptake Confirmed | no |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | |
| Peptide Concentration | Complex solution applied topically; exact OK-102 amount not explicitly stated (N/P=10). |
| Rna Concentration | 0.375 nmol RNAi agent per administration (nkRNA or PnkRNA) complexed with OK-102; repeated dosing over 2 weeks. |
| Mixing Ratio | OK-102 complexes prepared at N/P (nitrogen:phosphorous) ratio = 10; mixed 30 min at room temperature before use. |
| Formulation Format | CPP peptide/RNA electrostatic complex (cytoplasm-responsive nanocarrier with disulfide crosslinking) |
| Formulation Components | OK-102 (stearoyl-CHHRRRRHHC) complexed with anti-RelA nkRNA1 or PnkRNA1. |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | |
| Animal Model | NC/Nga mouse model of atopic dermatitis (DNFB-induced ear lesions) |
| Administration Route | Topical transdermal administration to left ear with olive oil cover; 2–3×/week for 2 weeks (days 3,4,7,11,12) |
| Output Type | In vivo therapeutic/phenotypic effect in AD model: ear thickness, clinical score, cytokines (TNF-α, IL-6) |
| Output Value | Suppressed DNFB-induced increases in ear thickness and clinical score; significantly reduced TNF-α and IL-6 vs untreated/scrambled groups. |
| Output Units | |
| Output Notes | Non-invasive topical RNAi therapy for AD-like lesions; no adverse reactions reported. |
| Toxicity Notes | |
| Curation Notes |